Cigna's Financial Success Driven by Biosimilar Demand
Cigna exceeded Wall Street expectations for third-quarter profits thanks to increased demand for biosimilars and growth in its pharmacy benefit management unit. Despite a drop in net income due to investment losses, the company maintained a strong revenue stream and benefited from distributing Humira biosimilars.
Cigna far surpassed Wall Street's third-quarter profit forecasts, largely due to robust demand for biosimilars and the acquisition of new clients by its pharmacy benefit management unit.
The healthcare conglomerate reported a rise in total adjusted revenue by 36%, reaching $52.64 billion in its Evernorth healthcare services unit. Cigna continues to expand beyond AbbVie's Humira, predicting the U.S. market for biosimilars will surpass $100 billion annually by 2030.
Quarterly net income fell by 47.5% due to investment losses associated with VillageMD. However, Cigna upheld its annual forecast, demonstrating a resilient profit margin despite higher medical care ratios.
(With inputs from agencies.)
- READ MORE ON:
- Cigna
- third-quarter
- profit
- biosimilars
- Humira
- pharmacy
- healthcare
- insurance
- revenue
- growth
ALSO READ
Healthcare Upgradation in West Bengal Following Tragic Incident
NCLAT Dismisses Insolvency Proceedings Against Jaypee Healthcare After Max Healthcare Settlement
Haryana's Bold Healthcare and Social Reforms Unveiled
Driving Quality Healthcare: A New Toolkit for Monitoring Maternal and Child Health
Healthcare Revolution: ESIC and Ayushman Bharat Collaborate